search
Back to results

Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use

Primary Purpose

Healthy

Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Ad26.COV2.S
Sponsored by
Janssen Research & Development, LLC
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Healthy

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    March 24, 2021
    Last Updated
    March 24, 2021
    Sponsor
    Janssen Research & Development, LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04817657
    Brief Title
    Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use
    Official Title
    COVID Vaccine VAC31518 Pre-approval Access Study
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    March 2021
    Overall Recruitment Status
    No longer available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Janssen Research & Development, LLC

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this Pre-approval access (PAA) program is to provide VAC31518 (Ad26.CoV2.S) vaccine for the prevention of coronavirus disease-2019 (COVID-19) infection. This PAA program may be considered to protect participants against a serious/life-threatening diseases or conditions, where there are no alternative treatments available.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Healthy

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Biological
    Intervention Name(s)
    Ad26.COV2.S
    Other Intervention Name(s)
    VAC31518, JNJ-78436735
    Intervention Description
    Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1*10^11 virus particles per milliliter (vp/ml) as intramuscular injection.

    10. Eligibility

    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Janssen Research & Development, LLC Clinical Trial
    Organizational Affiliation
    Janssen Research & Development, LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use

    We'll reach out to this number within 24 hrs